It doesn't take a political genius to see the writing on the wall regarding biosimilars. Our third top story today concerns a new pact to develop a biosimilar in Europe. As more of these deals take shape in Europe, they will add to the political pressure to create a regulatory pathway for generic biotech therapies in the U.S. This has become a mantra for payers in the U.S. demanding price relief, and the new Democratic majority in Congress is likely to view this in only one way.
I'm taking the rest of the week off for a Thanksgiving vacation. Associate Editor, Maureen Martino will be the report on Tuesday and Wednesday before our regular holiday break. If you have anything to send to FierceBiotech that demands immediate attention, she's your best contact. Until next Monday, have a great holiday break. - John Carroll